Industry Research Reports
Global Broluzumab Biosimilars Market Research Report 2024
Industry: Pharma & Healthcare
Published Date: 2024-01-20
Pages: 109 Pages
Report ld: 2755749
Request Sample
Customized Report
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
Brolucizumab is a humanized single-chain antibody fragment for the treatment of neovascular (wet) age-related macular degeneration (AMD). The most common side effects are reduced visual acuity, cataract (clouding of the lens in the eye), conjunctival haemorrhage (bleeding at the front of the eye) and vitreous floaters (spots in the vision). The most serious side effects are blindness, endophthalmitis (an infection inside the eye), retinal artery occlusion (blockage of the artery in the retina) and retinal detachment (separation of the retina from the back of the eye). Brolucizumab was designed to attach to and block a substance called vascular endothelial growth factor A (VEGF-A). VEGF-A is a protein that makes blood vessels grow and leak fluid and blood, damaging the macula. By blocking VEGF-A, brolucizumab reduces the growth of the blood vessels and controls the leakage and swelling.
The global Broluzumab Biosimilars market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Broluzumab Biosimilars, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Broluzumab Biosimilars.
MARKET SEGMENTATION
By Company
- Novartis
- Genentech
- Roche
- Pfizer
- Sartorius
- Eli Lilly
- Bayer
- Amgen
- PlantForm
- PharmaPraxis
- Samsung Bioepis
- Centus
- Cadila Pharmaceuticals
- Dr Reddy's
- Aurobindo Pharma
- Biocad
- MAbxience
- Hetero
- Biocon
- Kirin Biologics
- Mylan
- BeiGene
- Innovent
- Qilu Pharmaceutical
- Hengrui Pharmaceuticals
- Hisun Pharmaceutical
- TOT BIOPHARM
- Luye Pharmaceutical
- Henlius
Consumption by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Segment by Type
- Beovu
- Vsiqq
- Others
Segment by Application
- ARMD
- Kaposi Sarcoma
- Glioblastoma
REPORT SCOPE
The Broluzumab Biosimilars market size, estimations, and forecasts are provided in terms of sales volume (Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Broluzumab Biosimilars market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Broluzumab Biosimilars manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
CHAPTER OUTLINE
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Broluzumab Biosimilars manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Broluzumab Biosimilars in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
Market entry risks/opportunities by region
We identify regional market threats and growth prospects to guide your overseas layout.
Product mix optimization based on local practices
We adjust product portfolios in line with local consumption habits.
Competitor tactics in fragmented vs. consolidated markets
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
Full Research Coverage
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
19 Years Industry Expertise
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
24/7 Fast Report Delivery
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
Localized Strategic Analysis
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
Market entry risks/opportunities by region
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
Market entry risks/opportunities by region
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Broluzumab Biosimilars Market Overview
1.1 Product Overview and Scope of Broluzumab Biosimilars
1.2 Broluzumab Biosimilars Segment by Type
1.2.1 Global Broluzumab Biosimilars Market Value Comparison by Type (2024-2030)
1.2.2 Beovu
1.2.3 Vsiqq
1.2.4 Others
1.3 Broluzumab Biosimilars Segment by Application
1.3.1 Global Broluzumab Biosimilars Market Value by Application: (2024-2030)
1.3.2 ARMD
1.3.3 Kaposi Sarcoma
1.3.4 Glioblastoma
1.4 Global Broluzumab Biosimilars Market Size Estimates and Forecasts
1.4.1 Global Broluzumab Biosimilars Revenue 2019-2030
1.4.2 Global Broluzumab Biosimilars Sales 2019-2030
1.4.3 Global Broluzumab Biosimilars Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Broluzumab Biosimilars Market Competition by Manufacturers
2.1 Global Broluzumab Biosimilars Sales Market Share by Manufacturers (2019-2024)
2.2 Global Broluzumab Biosimilars Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Broluzumab Biosimilars Average Price by Manufacturers (2019-2024)
2.4 Global Broluzumab Biosimilars Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Broluzumab Biosimilars, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Broluzumab Biosimilars, Product Type & Application
2.7 Broluzumab Biosimilars Market Competitive Situation and Trends
2.7.1 Broluzumab Biosimilars Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Broluzumab Biosimilars Players Market Share by Revenue
2.7.3 Global Broluzumab Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Broluzumab Biosimilars Retrospective Market Scenario by Region
3.1 Global Broluzumab Biosimilars Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Broluzumab Biosimilars Global Broluzumab Biosimilars Sales by Region: 2019-2030
3.2.1 Global Broluzumab Biosimilars Sales by Region: 2019-2024
3.2.2 Global Broluzumab Biosimilars Sales by Region: 2025-2030
3.3 Global Broluzumab Biosimilars Global Broluzumab Biosimilars Revenue by Region: 2019-2030
3.3.1 Global Broluzumab Biosimilars Revenue by Region: 2019-2024
3.3.2 Global Broluzumab Biosimilars Revenue by Region: 2025-2030
3.4 North America Broluzumab Biosimilars Market Facts & Figures by Country
3.4.1 North America Broluzumab Biosimilars Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Broluzumab Biosimilars Sales by Country (2019-2030)
3.4.3 North America Broluzumab Biosimilars Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Broluzumab Biosimilars Market Facts & Figures by Country
3.5.1 Europe Broluzumab Biosimilars Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Broluzumab Biosimilars Sales by Country (2019-2030)
3.5.3 Europe Broluzumab Biosimilars Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Broluzumab Biosimilars Market Facts & Figures by Country
3.6.1 Asia Pacific Broluzumab Biosimilars Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Broluzumab Biosimilars Sales by Country (2019-2030)
3.6.3 Asia Pacific Broluzumab Biosimilars Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Broluzumab Biosimilars Market Facts & Figures by Country
3.7.1 Latin America Broluzumab Biosimilars Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Broluzumab Biosimilars Sales by Country (2019-2030)
3.7.3 Latin America Broluzumab Biosimilars Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Broluzumab Biosimilars Market Facts & Figures by Country
3.8.1 Middle East and Africa Broluzumab Biosimilars Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Broluzumab Biosimilars Sales by Country (2019-2030)
3.8.3 Middle East and Africa Broluzumab Biosimilars Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Broluzumab Biosimilars Sales by Type (2019-2030)
4.1.1 Global Broluzumab Biosimilars Sales by Type (2019-2024)
4.1.2 Global Broluzumab Biosimilars Sales by Type (2025-2030)
4.1.3 Global Broluzumab Biosimilars Sales Market Share by Type (2019-2030)
4.2 Global Broluzumab Biosimilars Revenue by Type (2019-2030)
4.2.1 Global Broluzumab Biosimilars Revenue by Type (2019-2024)
4.2.2 Global Broluzumab Biosimilars Revenue by Type (2025-2030)
4.2.3 Global Broluzumab Biosimilars Revenue Market Share by Type (2019-2030)
4.3 Global Broluzumab Biosimilars Price by Type (2019-2030)
5 Segment by Application
5.1 Global Broluzumab Biosimilars Sales by Application (2019-2030)
5.1.1 Global Broluzumab Biosimilars Sales by Application (2019-2024)
5.1.2 Global Broluzumab Biosimilars Sales by Application (2025-2030)
5.1.3 Global Broluzumab Biosimilars Sales Market Share by Application (2019-2030)
5.2 Global Broluzumab Biosimilars Revenue by Application (2019-2030)
5.2.1 Global Broluzumab Biosimilars Revenue by Application (2019-2024)
5.2.2 Global Broluzumab Biosimilars Revenue by Application (2025-2030)
5.2.3 Global Broluzumab Biosimilars Revenue Market Share by Application (2019-2030)
5.3 Global Broluzumab Biosimilars Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Novartis
6.1.1 Novartis Corporation Information
6.1.2 Novartis Description and Business Overview
6.1.3 Novartis Broluzumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Novartis Broluzumab Biosimilars Product Portfolio
6.1.5 Novartis Recent Developments/Updates
6.2 Genentech
6.2.1 Genentech Corporation Information
6.2.2 Genentech Description and Business Overview
6.2.3 Genentech Broluzumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Genentech Broluzumab Biosimilars Product Portfolio
6.2.5 Genentech Recent Developments/Updates
6.3 Roche
6.3.1 Roche Corporation Information
6.3.2 Roche Description and Business Overview
6.3.3 Roche Broluzumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Roche Broluzumab Biosimilars Product Portfolio
6.3.5 Roche Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Corporation Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer Broluzumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Pfizer Broluzumab Biosimilars Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 Sartorius
6.5.1 Sartorius Corporation Information
6.5.2 Sartorius Description and Business Overview
6.5.3 Sartorius Broluzumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Sartorius Broluzumab Biosimilars Product Portfolio
6.5.5 Sartorius Recent Developments/Updates
6.6 Eli Lilly
6.6.1 Eli Lilly Corporation Information
6.6.2 Eli Lilly Description and Business Overview
6.6.3 Eli Lilly Broluzumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Eli Lilly Broluzumab Biosimilars Product Portfolio
6.6.5 Eli Lilly Recent Developments/Updates
6.7 Bayer
6.6.1 Bayer Corporation Information
6.6.2 Bayer Description and Business Overview
6.6.3 Bayer Broluzumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Bayer Broluzumab Biosimilars Product Portfolio
6.7.5 Bayer Recent Developments/Updates
6.8 Amgen
6.8.1 Amgen Corporation Information
6.8.2 Amgen Description and Business Overview
6.8.3 Amgen Broluzumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Amgen Broluzumab Biosimilars Product Portfolio
6.8.5 Amgen Recent Developments/Updates
6.9 PlantForm
6.9.1 PlantForm Corporation Information
6.9.2 PlantForm Description and Business Overview
6.9.3 PlantForm Broluzumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.9.4 PlantForm Broluzumab Biosimilars Product Portfolio
6.9.5 PlantForm Recent Developments/Updates
6.10 PharmaPraxis
6.10.1 PharmaPraxis Corporation Information
6.10.2 PharmaPraxis Description and Business Overview
6.10.3 PharmaPraxis Broluzumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.10.4 PharmaPraxis Broluzumab Biosimilars Product Portfolio
6.10.5 PharmaPraxis Recent Developments/Updates
6.11 Samsung Bioepis
6.11.1 Samsung Bioepis Corporation Information
6.11.2 Samsung Bioepis Broluzumab Biosimilars Description and Business Overview
6.11.3 Samsung Bioepis Broluzumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Samsung Bioepis Broluzumab Biosimilars Product Portfolio
6.11.5 Samsung Bioepis Recent Developments/Updates
6.12 Centus
6.12.1 Centus Corporation Information
6.12.2 Centus Broluzumab Biosimilars Description and Business Overview
6.12.3 Centus Broluzumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Centus Broluzumab Biosimilars Product Portfolio
6.12.5 Centus Recent Developments/Updates
6.13 Cadila Pharmaceuticals
6.13.1 Cadila Pharmaceuticals Corporation Information
6.13.2 Cadila Pharmaceuticals Broluzumab Biosimilars Description and Business Overview
6.13.3 Cadila Pharmaceuticals Broluzumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Cadila Pharmaceuticals Broluzumab Biosimilars Product Portfolio
6.13.5 Cadila Pharmaceuticals Recent Developments/Updates
6.14 Dr Reddy's
6.14.1 Dr Reddy's Corporation Information
6.14.2 Dr Reddy's Broluzumab Biosimilars Description and Business Overview
6.14.3 Dr Reddy's Broluzumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Dr Reddy's Broluzumab Biosimilars Product Portfolio
6.14.5 Dr Reddy's Recent Developments/Updates
6.15 Aurobindo Pharma
6.15.1 Aurobindo Pharma Corporation Information
6.15.2 Aurobindo Pharma Broluzumab Biosimilars Description and Business Overview
6.15.3 Aurobindo Pharma Broluzumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Aurobindo Pharma Broluzumab Biosimilars Product Portfolio
6.15.5 Aurobindo Pharma Recent Developments/Updates
6.16 Biocad
6.16.1 Biocad Corporation Information
6.16.2 Biocad Broluzumab Biosimilars Description and Business Overview
6.16.3 Biocad Broluzumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Biocad Broluzumab Biosimilars Product Portfolio
6.16.5 Biocad Recent Developments/Updates
6.17 MAbxience
6.17.1 MAbxience Corporation Information
6.17.2 MAbxience Broluzumab Biosimilars Description and Business Overview
6.17.3 MAbxience Broluzumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.17.4 MAbxience Broluzumab Biosimilars Product Portfolio
6.17.5 MAbxience Recent Developments/Updates
6.18 Hetero
6.18.1 Hetero Corporation Information
6.18.2 Hetero Broluzumab Biosimilars Description and Business Overview
6.18.3 Hetero Broluzumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.18.4 Hetero Broluzumab Biosimilars Product Portfolio
6.18.5 Hetero Recent Developments/Updates
6.19 Biocon
6.19.1 Biocon Corporation Information
6.19.2 Biocon Broluzumab Biosimilars Description and Business Overview
6.19.3 Biocon Broluzumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.19.4 Biocon Broluzumab Biosimilars Product Portfolio
6.19.5 Biocon Recent Developments/Updates
6.20 Kirin Biologics
6.20.1 Kirin Biologics Corporation Information
6.20.2 Kirin Biologics Broluzumab Biosimilars Description and Business Overview
6.20.3 Kirin Biologics Broluzumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.20.4 Kirin Biologics Broluzumab Biosimilars Product Portfolio
6.20.5 Kirin Biologics Recent Developments/Updates
6.21 Mylan
6.21.1 Mylan Corporation Information
6.21.2 Mylan Broluzumab Biosimilars Description and Business Overview
6.21.3 Mylan Broluzumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.21.4 Mylan Broluzumab Biosimilars Product Portfolio
6.21.5 Mylan Recent Developments/Updates
6.22 BeiGene
6.22.1 BeiGene Corporation Information
6.22.2 BeiGene Broluzumab Biosimilars Description and Business Overview
6.22.3 BeiGene Broluzumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.22.4 BeiGene Broluzumab Biosimilars Product Portfolio
6.22.5 BeiGene Recent Developments/Updates
6.23 Innovent
6.23.1 Innovent Corporation Information
6.23.2 Innovent Broluzumab Biosimilars Description and Business Overview
6.23.3 Innovent Broluzumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.23.4 Innovent Broluzumab Biosimilars Product Portfolio
6.23.5 Innovent Recent Developments/Updates
6.24 Qilu Pharmaceutical
6.24.1 Qilu Pharmaceutical Corporation Information
6.24.2 Qilu Pharmaceutical Broluzumab Biosimilars Description and Business Overview
6.24.3 Qilu Pharmaceutical Broluzumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.24.4 Qilu Pharmaceutical Broluzumab Biosimilars Product Portfolio
6.24.5 Qilu Pharmaceutical Recent Developments/Updates
6.25 Hengrui Pharmaceuticals
6.25.1 Hengrui Pharmaceuticals Corporation Information
6.25.2 Hengrui Pharmaceuticals Broluzumab Biosimilars Description and Business Overview
6.25.3 Hengrui Pharmaceuticals Broluzumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.25.4 Hengrui Pharmaceuticals Broluzumab Biosimilars Product Portfolio
6.25.5 Hengrui Pharmaceuticals Recent Developments/Updates
6.26 Hisun Pharmaceutical
6.26.1 Hisun Pharmaceutical Corporation Information
6.26.2 Hisun Pharmaceutical Broluzumab Biosimilars Description and Business Overview
6.26.3 Hisun Pharmaceutical Broluzumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.26.4 Hisun Pharmaceutical Broluzumab Biosimilars Product Portfolio
6.26.5 Hisun Pharmaceutical Recent Developments/Updates
6.27 TOT BIOPHARM
6.27.1 TOT BIOPHARM Corporation Information
6.27.2 TOT BIOPHARM Broluzumab Biosimilars Description and Business Overview
6.27.3 TOT BIOPHARM Broluzumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.27.4 TOT BIOPHARM Broluzumab Biosimilars Product Portfolio
6.27.5 TOT BIOPHARM Recent Developments/Updates
6.28 Luye Pharmaceutical
6.28.1 Luye Pharmaceutical Corporation Information
6.28.2 Luye Pharmaceutical Broluzumab Biosimilars Description and Business Overview
6.28.3 Luye Pharmaceutical Broluzumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.28.4 Luye Pharmaceutical Broluzumab Biosimilars Product Portfolio
6.28.5 Luye Pharmaceutical Recent Developments/Updates
6.29 Henlius
6.29.1 Henlius Corporation Information
6.29.2 Henlius Broluzumab Biosimilars Description and Business Overview
6.29.3 Henlius Broluzumab Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.29.4 Henlius Broluzumab Biosimilars Product Portfolio
6.29.5 Henlius Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Broluzumab Biosimilars Industry Chain Analysis
7.2 Broluzumab Biosimilars Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Broluzumab Biosimilars Production Mode & Process
7.4 Broluzumab Biosimilars Sales and Marketing
7.4.1 Broluzumab Biosimilars Sales Channels
7.4.2 Broluzumab Biosimilars Distributors
7.5 Broluzumab Biosimilars Customers
8 Broluzumab Biosimilars Market Dynamics
8.1 Broluzumab Biosimilars Industry Trends
8.2 Broluzumab Biosimilars Market Drivers
8.3 Broluzumab Biosimilars Market Challenges
8.4 Broluzumab Biosimilars Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
TABLE OF FIGURES
List of Tables
Table 1. Global Broluzumab Biosimilars Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Broluzumab Biosimilars Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Broluzumab Biosimilars Market Competitive Situation by Manufacturers in 2023
Table 4. Global Broluzumab Biosimilars Sales (Units) of Key Manufacturers (2019-2024)
Table 5. Global Broluzumab Biosimilars Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Broluzumab Biosimilars Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Broluzumab Biosimilars Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Broluzumab Biosimilars Average Price (K USD/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Broluzumab Biosimilars, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Broluzumab Biosimilars, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Broluzumab Biosimilars, Product Type & Application
Table 12. Global Key Manufacturers of Broluzumab Biosimilars, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Broluzumab Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Broluzumab Biosimilars as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Broluzumab Biosimilars Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Broluzumab Biosimilars Sales by Region (2019-2024) & (Units)
Table 18. Global Broluzumab Biosimilars Sales Market Share by Region (2019-2024)
Table 19. Global Broluzumab Biosimilars Sales by Region (2025-2030) & (Units)
Table 20. Global Broluzumab Biosimilars Sales Market Share by Region (2025-2030)
Table 21. Global Broluzumab Biosimilars Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Broluzumab Biosimilars Revenue Market Share by Region (2019-2024)
Table 23. Global Broluzumab Biosimilars Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Broluzumab Biosimilars Revenue Market Share by Region (2025-2030)
Table 25. North America Broluzumab Biosimilars Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Broluzumab Biosimilars Sales by Country (2019-2024) & (Units)
Table 27. North America Broluzumab Biosimilars Sales by Country (2025-2030) & (Units)
Table 28. North America Broluzumab Biosimilars Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Broluzumab Biosimilars Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Broluzumab Biosimilars Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Broluzumab Biosimilars Sales by Country (2019-2024) & (Units)
Table 32. Europe Broluzumab Biosimilars Sales by Country (2025-2030) & (Units)
Table 33. Europe Broluzumab Biosimilars Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Broluzumab Biosimilars Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Broluzumab Biosimilars Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Broluzumab Biosimilars Sales by Region (2019-2024) & (Units)
Table 37. Asia Pacific Broluzumab Biosimilars Sales by Region (2025-2030) & (Units)
Table 38. Asia Pacific Broluzumab Biosimilars Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Broluzumab Biosimilars Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Broluzumab Biosimilars Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Broluzumab Biosimilars Sales by Country (2019-2024) & (Units)
Table 42. Latin America Broluzumab Biosimilars Sales by Country (2025-2030) & (Units)
Table 43. Latin America Broluzumab Biosimilars Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Broluzumab Biosimilars Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Broluzumab Biosimilars Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Broluzumab Biosimilars Sales by Country (2019-2024) & (Units)
Table 47. Middle East & Africa Broluzumab Biosimilars Sales by Country (2025-2030) & (Units)
Table 48. Middle East & Africa Broluzumab Biosimilars Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Broluzumab Biosimilars Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Broluzumab Biosimilars Sales (Units) by Type (2019-2024)
Table 51. Global Broluzumab Biosimilars Sales (Units) by Type (2025-2030)
Table 52. Global Broluzumab Biosimilars Sales Market Share by Type (2019-2024)
Table 53. Global Broluzumab Biosimilars Sales Market Share by Type (2025-2030)
Table 54. Global Broluzumab Biosimilars Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Broluzumab Biosimilars Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Broluzumab Biosimilars Revenue Market Share by Type (2019-2024)
Table 57. Global Broluzumab Biosimilars Revenue Market Share by Type (2025-2030)
Table 58. Global Broluzumab Biosimilars Price (K USD/Unit) by Type (2019-2024)
Table 59. Global Broluzumab Biosimilars Price (K USD/Unit) by Type (2025-2030)
Table 60. Global Broluzumab Biosimilars Sales (Units) by Application (2019-2024)
Table 61. Global Broluzumab Biosimilars Sales (Units) by Application (2025-2030)
Table 62. Global Broluzumab Biosimilars Sales Market Share by Application (2019-2024)
Table 63. Global Broluzumab Biosimilars Sales Market Share by Application (2025-2030)
Table 64. Global Broluzumab Biosimilars Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Broluzumab Biosimilars Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Broluzumab Biosimilars Revenue Market Share by Application (2019-2024)
Table 67. Global Broluzumab Biosimilars Revenue Market Share by Application (2025-2030)
Table 68. Global Broluzumab Biosimilars Price (K USD/Unit) by Application (2019-2024)
Table 69. Global Broluzumab Biosimilars Price (K USD/Unit) by Application (2025-2030)
Table 70. Novartis Corporation Information
Table 71. Novartis Description and Business Overview
Table 72. Novartis Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2019-2024)
Table 73. Novartis Broluzumab Biosimilars Product
Table 74. Novartis Recent Developments/Updates
Table 75. Genentech Corporation Information
Table 76. Genentech Description and Business Overview
Table 77. Genentech Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2019-2024)
Table 78. Genentech Broluzumab Biosimilars Product
Table 79. Genentech Recent Developments/Updates
Table 80. Roche Corporation Information
Table 81. Roche Description and Business Overview
Table 82. Roche Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2019-2024)
Table 83. Roche Broluzumab Biosimilars Product
Table 84. Roche Recent Developments/Updates
Table 85. Pfizer Corporation Information
Table 86. Pfizer Description and Business Overview
Table 87. Pfizer Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2019-2024)
Table 88. Pfizer Broluzumab Biosimilars Product
Table 89. Pfizer Recent Developments/Updates
Table 90. Sartorius Corporation Information
Table 91. Sartorius Description and Business Overview
Table 92. Sartorius Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2019-2024)
Table 93. Sartorius Broluzumab Biosimilars Product
Table 94. Sartorius Recent Developments/Updates
Table 95. Eli Lilly Corporation Information
Table 96. Eli Lilly Description and Business Overview
Table 97. Eli Lilly Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2019-2024)
Table 98. Eli Lilly Broluzumab Biosimilars Product
Table 99. Eli Lilly Recent Developments/Updates
Table 100. Bayer Corporation Information
Table 101. Bayer Description and Business Overview
Table 102. Bayer Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2019-2024)
Table 103. Bayer Broluzumab Biosimilars Product
Table 104. Bayer Recent Developments/Updates
Table 105. Amgen Corporation Information
Table 106. Amgen Description and Business Overview
Table 107. Amgen Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2019-2024)
Table 108. Amgen Broluzumab Biosimilars Product
Table 109. Amgen Recent Developments/Updates
Table 110. PlantForm Corporation Information
Table 111. PlantForm Description and Business Overview
Table 112. PlantForm Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2019-2024)
Table 113. PlantForm Broluzumab Biosimilars Product
Table 114. PlantForm Recent Developments/Updates
Table 115. PharmaPraxis Corporation Information
Table 116. PharmaPraxis Description and Business Overview
Table 117. PharmaPraxis Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2019-2024)
Table 118. PharmaPraxis Broluzumab Biosimilars Product
Table 119. PharmaPraxis Recent Developments/Updates
Table 120. Samsung Bioepis Corporation Information
Table 121. Samsung Bioepis Description and Business Overview
Table 122. Samsung Bioepis Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2019-2024)
Table 123. Samsung Bioepis Broluzumab Biosimilars Product
Table 124. Samsung Bioepis Recent Developments/Updates
Table 125. Centus Corporation Information
Table 126. Centus Description and Business Overview
Table 127. Centus Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2019-2024)
Table 128. Centus Broluzumab Biosimilars Product
Table 129. Centus Recent Developments/Updates
Table 130. Cadila Pharmaceuticals Corporation Information
Table 131. Cadila Pharmaceuticals Description and Business Overview
Table 132. Cadila Pharmaceuticals Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2019-2024)
Table 133. Cadila Pharmaceuticals Broluzumab Biosimilars Product
Table 134. Cadila Pharmaceuticals Recent Developments/Updates
Table 135. Dr Reddy's Corporation Information
Table 136. Dr Reddy's Description and Business Overview
Table 137. Dr Reddy's Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2019-2024)
Table 138. Dr Reddy's Broluzumab Biosimilars Product
Table 139. Dr Reddy's Recent Developments/Updates
Table 140. Aurobindo Pharma Corporation Information
Table 141. Aurobindo Pharma Description and Business Overview
Table 142. Aurobindo Pharma Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2019-2024)
Table 143. Aurobindo Pharma Broluzumab Biosimilars Product
Table 144. Aurobindo Pharma Recent Developments/Updates
Table 145. Biocad Corporation Information
Table 146. Biocad Description and Business Overview
Table 147. Biocad Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2019-2024)
Table 148. Biocad Broluzumab Biosimilars Product
Table 149. Biocad Recent Developments/Updates
Table 150. MAbxience Corporation Information
Table 151. MAbxience Description and Business Overview
Table 152. MAbxience Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2019-2024)
Table 153. MAbxience Broluzumab Biosimilars Product
Table 154. MAbxience Recent Developments/Updates
Table 155. Hetero Corporation Information
Table 156. Hetero Description and Business Overview
Table 157. Hetero Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2019-2024)
Table 158. Hetero Broluzumab Biosimilars Product
Table 159. Hetero Recent Developments/Updates
Table 160. Biocon Corporation Information
Table 161. Biocon Description and Business Overview
Table 162. Biocon Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2019-2024)
Table 163. Biocon Broluzumab Biosimilars Product
Table 164. Biocon Recent Developments/Updates
Table 165. Kirin Biologics Corporation Information
Table 166. Kirin Biologics Description and Business Overview
Table 167. Kirin Biologics Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2019-2024)
Table 168. Kirin Biologics Broluzumab Biosimilars Product
Table 169. Kirin Biologics Recent Developments/Updates
Table 170. Mylan Corporation Information
Table 171. Mylan Description and Business Overview
Table 172. Mylan Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2019-2024)
Table 173. Mylan Broluzumab Biosimilars Product
Table 174. Mylan Recent Developments/Updates
Table 175. BeiGene Corporation Information
Table 176. BeiGene Description and Business Overview
Table 177. BeiGene Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2019-2024)
Table 178. BeiGene Broluzumab Biosimilars Product
Table 179. BeiGene Recent Developments/Updates
Table 180. Innovent Corporation Information
Table 181. Innovent Description and Business Overview
Table 182. Innovent Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2019-2024)
Table 183. Innovent Broluzumab Biosimilars Product
Table 184. Innovent Recent Developments/Updates
Table 185. Qilu Pharmaceutical Corporation Information
Table 186. Qilu Pharmaceutical Description and Business Overview
Table 187. Qilu Pharmaceutical Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2019-2024)
Table 188. Qilu Pharmaceutical Broluzumab Biosimilars Product
Table 189. Qilu Pharmaceutical Recent Developments/Updates
Table 190. Hengrui Pharmaceuticals Corporation Information
Table 191. Hengrui Pharmaceuticals Description and Business Overview
Table 192. Hengrui Pharmaceuticals Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2019-2024)
Table 193. Hengrui Pharmaceuticals Broluzumab Biosimilars Product
Table 194. Hengrui Pharmaceuticals Recent Developments/Updates
Table 195. Hisun Pharmaceutical Corporation Information
Table 196. Hisun Pharmaceutical Description and Business Overview
Table 197. Hisun Pharmaceutical Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2019-2024)
Table 198. Hisun Pharmaceutical Broluzumab Biosimilars Product
Table 199. Hisun Pharmaceutical Recent Developments/Updates
Table 200. TOT BIOPHARM Corporation Information
Table 201. TOT BIOPHARM Description and Business Overview
Table 202. TOT BIOPHARM Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2019-2024)
Table 203. TOT BIOPHARM Broluzumab Biosimilars Product
Table 204. TOT BIOPHARM Recent Developments/Updates
Table 205. Luye Pharmaceutical Corporation Information
Table 206. Luye Pharmaceutical Description and Business Overview
Table 207. Luye Pharmaceutical Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2019-2024)
Table 208. Luye Pharmaceutical Broluzumab Biosimilars Product
Table 209. Luye Pharmaceutical Recent Developments/Updates
Table 210. Henlius Corporation Information
Table 211. Henlius Description and Business Overview
Table 212. Henlius Broluzumab Biosimilars Sales (Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2019-2024)
Table 213. Henlius Broluzumab Biosimilars Product
Table 214. Henlius Recent Developments/Updates
Table 215. Key Raw Materials Lists
Table 216. Raw Materials Key Suppliers Lists
Table 217. Broluzumab Biosimilars Distributors List
Table 218. Broluzumab Biosimilars Customers List
Table 219. Broluzumab Biosimilars Market Trends
Table 220. Broluzumab Biosimilars Market Drivers
Table 221. Broluzumab Biosimilars Market Challenges
Table 222. Broluzumab Biosimilars Market Restraints
Table 223. Research Programs/Design for This Report
Table 224. Key Data Information from Secondary Sources
Table 225. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Broluzumab Biosimilars
Figure 2. Global Broluzumab Biosimilars Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Broluzumab Biosimilars Market Share by Type in 2023 & 2030
Figure 4. Beovu Product Picture
Figure 5. Vsiqq Product Picture
Figure 6. Others Product Picture
Figure 7. Global Broluzumab Biosimilars Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Broluzumab Biosimilars Market Share by Application in 2023 & 2030
Figure 9. ARMD
Figure 10. Kaposi Sarcoma
Figure 11. Glioblastoma
Figure 12. Global Broluzumab Biosimilars Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 13. Global Broluzumab Biosimilars Market Size (2019-2030) & (US$ Million)
Figure 14. Global Broluzumab Biosimilars Sales (2019-2030) & (Units)
Figure 15. Global Broluzumab Biosimilars Average Price (K USD/Unit) & (2019-2030)
Figure 16. Broluzumab Biosimilars Report Years Considered
Figure 17. Broluzumab Biosimilars Sales Share by Manufacturers in 2023
Figure 18. Global Broluzumab Biosimilars Revenue Share by Manufacturers in 2023
Figure 19. The Global 5 and 10 Largest Broluzumab Biosimilars Players: Market Share by Revenue in 2023
Figure 20. Broluzumab Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 21. Global Broluzumab Biosimilars Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 22. North America Broluzumab Biosimilars Sales Market Share by Country (2019-2030)
Figure 23. North America Broluzumab Biosimilars Revenue Market Share by Country (2019-2030)
Figure 24. U.S. Broluzumab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 25. Canada Broluzumab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 26. Europe Broluzumab Biosimilars Sales Market Share by Country (2019-2030)
Figure 27. Europe Broluzumab Biosimilars Revenue Market Share by Country (2019-2030)
Figure 28. Germany Broluzumab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. France Broluzumab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. U.K. Broluzumab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Italy Broluzumab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Russia Broluzumab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. Asia Pacific Broluzumab Biosimilars Sales Market Share by Region (2019-2030)
Figure 34. Asia Pacific Broluzumab Biosimilars Revenue Market Share by Region (2019-2030)
Figure 35. China Broluzumab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. Japan Broluzumab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. South Korea Broluzumab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. India Broluzumab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Australia Broluzumab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Taiwan Broluzumab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Indonesia Broluzumab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Thailand Broluzumab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Malaysia Broluzumab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Philippines Broluzumab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Latin America Broluzumab Biosimilars Sales Market Share by Country (2019-2030)
Figure 46. Latin America Broluzumab Biosimilars Revenue Market Share by Country (2019-2030)
Figure 47. Mexico Broluzumab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Brazil Broluzumab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. Argentina Broluzumab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 50. Middle East & Africa Broluzumab Biosimilars Sales Market Share by Country (2019-2030)
Figure 51. Middle East & Africa Broluzumab Biosimilars Revenue Market Share by Country (2019-2030)
Figure 52. Turkey Broluzumab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. Saudi Arabia Broluzumab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 54. U.A.E Broluzumab Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 55. Global Sales Market Share of Broluzumab Biosimilars by Type (2019-2030)
Figure 56. Global Revenue Market Share of Broluzumab Biosimilars by Type (2019-2030)
Figure 57. Global Broluzumab Biosimilars Price (K USD/Unit) by Type (2019-2030)
Figure 58. Global Sales Market Share of Broluzumab Biosimilars by Application (2019-2030)
Figure 59. Global Revenue Market Share of Broluzumab Biosimilars by Application (2019-2030)
Figure 60. Global Broluzumab Biosimilars Price (K USD/Unit) by Application (2019-2030)
Figure 61. Broluzumab Biosimilars Value Chain
Figure 62. Broluzumab Biosimilars Production Process
Figure 63. Channels of Distribution (Direct Vs Distribution)
Figure 64. Distributors Profiles
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
KEY QUESTIONS ADDRESSED BY THE REPORT
Which companies rank high in the global Broluzumab Biosimilars market?
The top companies in the global Broluzumab Biosimilars market are Novartis、Genentech、Roche.
Related Reports
Broluzumab Biosimilars- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Broluzumab Biosimilars was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-01-16
Pages: 189
USD 3950.00
(Single User License)
Global Broluzumab Biosimilars Market Research Report 2025
The global market for Broluzumab Biosimilars was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published Date: 2025-01-16
Pages: 119
USD 2900.00
(Single User License)
Broluzumab Biosimilars - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Brolucizumab is a humanized single-chain antibody fragment for the treatment of neovascular (wet) age-related macular degeneration (AMD). The most common side effects are reduced visual acuity, cataract (clouding of the lens in the eye), conjunctival haemorrhage (bleeding at the front of the eye) and vitreous floaters (spots in the vision). The most serious side effects are blindness, endophthalmitis (an infection inside the eye), retinal artery occlusion (blockage of the artery in the retina) and retinal detachment (separation of the retina from the back of the eye). Brolucizumab was designed to attach to and block a substance called vascular endothelial growth factor A (VEGF-A). VEGF-A is a protein that makes blood vessels grow and leak fluid and blood, damaging the macula. By blocking VEGF-A, brolucizumab reduces the growth of the blood vessels and controls the leakage and swelling.
Published Date: 2024-01-11
Pages: 164
USD 3950.00
(Single User License)
Broluzumab Biosimilars- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Broluzumab Biosimilars was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-01-16
Pages: 189
USD 3950.00 (Single User License)Global Broluzumab Biosimilars Market Research Report 2025
The global market for Broluzumab Biosimilars was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published: 2025-01-16
Pages: 119
USD 2900.00 (Single User License)Broluzumab Biosimilars - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Brolucizumab is a humanized single-chain antibody fragment for the treatment of neovascular (wet) age-related macular degeneration (AMD). The most common side effects are reduced visual acuity, cataract (clouding of the lens in the eye), conjunctival haemorrhage (bleeding at the front of the eye) and vitreous floaters (spots in the vision). The most serious side effects are blindness, endophthalmitis (an infection inside the eye), retinal artery occlusion (blockage of the artery in the retina) and retinal detachment (separation of the retina from the back of the eye). Brolucizumab was designed to attach to and block a substance called vascular endothelial growth factor A (VEGF-A). VEGF-A is a protein that makes blood vessels grow and leak fluid and blood, damaging the macula. By blocking VEGF-A, brolucizumab reduces the growth of the blood vessels and controls the leakage and swelling.
Published: 2024-01-11
Pages: 164
USD 3950.00 (Single User License)
CHOOSE LICENSE TYPE
USD 2900.00
USD 4350.00
USD 5800.00
Add to Cart
Buy Now
HAVE A QUESTION?
General Email:
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
REPORT SCOPE
CHAPTER OUTLINE
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now